Literature DB >> 25535180

Mediastinoscopy-assisted oesophagectomy in T1 oesophageal cancer patients with serious comorbidities: a 5-year long-term follow-up.

Jun Wang1, Nan-Qing Jiang1, Bo Jiang1, Zhong-Lin Wang1, Xiao-Ying Zhang2.   

Abstract

OBJECTIVES: Transthoracic oesophagectomy is associated with high morbidity and mortality. Some oesophageal cancer (OC) patients with serious comorbidities cannot tolerate transthoracic oesophagectomy. Therefore, we have adopted a minimally invasive approach to oesophagectomy for such patients.
METHODS: Eighty-five OC patients, who could not tolerate transthoracic oesophagectomy, received mediastinoscopy-assisted oesophagectomy (MAO) from January 2007 to January 2010 in our hospital. Seventy patients were confirmed to be in T1 stage by postoperative pathological diagnosis, and their complications and outcomes were retrospectively analysed in this study. The impact of invasion depth, tumour length and lymph node metastases on the 5-year survival rate of these patients was also analysed.
RESULTS: The operation time was 150.0 ± 15.0 min, and the perioperative bleeding volume was 202.0 ± 12.8 ml. Some patients had anastomotic leakage (5 cases), pneumonia (4 cases) and chylothorax (1 case). No patient died during hospitalization. The median postoperative hospital stay was 10 (7-22) days. The number of lymph nodes resected was 13.8 ± 4.4. The overall 5-year survival rate was 71%. Kaplan-Meier estimates revealed that tumour length (<2 vs ≥ 2 cm), lymph node metastasis (N0 vs N1) and depth of invasion (T1a vs T1b) could influence the 5-year survival rate (P <0.05). Multivariate analysis by Cox regression showed that lymph node metastasis and tumour length were independent prognostic factors for the 5-year survival rate (P <0.05).
CONCLUSIONS: MAO could be performed for T1 OC patients with serious comorbidities who cannot tolerate transthoracic oesophagectomy. Lymph node metastasis and tumour length were independent prognostic factors for these patients.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Comorbidities; Mediastinoscopy-assisted oesophagectomy; Oesophageal cancer; Outcomes

Mesh:

Year:  2014        PMID: 25535180     DOI: 10.1093/icvts/ivu433

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  6 in total

1.  Mediastinoscopic esophagectomy for patients with early esophageal cancer.

Authors:  Qian-Yun Wang; Jing-Pei Li; Lei Zhang; Nan-Qing Jiang; Zhong-Lin Wang; Xiao-Ying Zhang
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  Comparison of Ivor Lewis and Sweet esophagectomy for middle and lower esophageal squamous cell carcinoma: A systematic review and pooled analysis.

Authors:  Yuhang Xue; Donglai Chen; Wei Wang; Wenjia Wang; Lei Chen; Yonghua Sang; Yongbing Chen; Weihua Xu
Journal:  EClinicalMedicine       Date:  2020-10-10

3.  Comparison of Ivor-Lewis versus Sweet procedure for middle and lower thoracic esophageal squamous cell carcinoma: A STROBE compliant study.

Authors:  Jun Wang; Ning Wei; Nanqing Jiang; Yiming Lu; Xiaoying Zhang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  Synchronous carcinoma of oesophageal and lung treated with laparoscopic-thoracoscopic cooperative surgery: A case report.

Authors:  Xin Li; Jiali Fu; Hua Zhang; Zhenguo Zhai; Wei Wang
Journal:  J Minim Access Surg       Date:  2019-04-24       Impact factor: 1.407

5.  Mediastinoscopy-assisted esophagectomy for T2 middle and lower thoracic esophageal squamous cell carcinoma patients.

Authors:  Jun Wang; Ning Wei; Yimin Lu; Xiaoying Zhang; Nanqing Jiang
Journal:  World J Surg Oncol       Date:  2018-03-16       Impact factor: 2.754

6.  Left minimally invasive esophagectomy in a patient with synchronous esophageal and lung cancers: Case report.

Authors:  Baihua Zhang; Junliang Ma; Xinjian Yan; Xu Li; Qin Xiao; Wenxiang Wang; Yong Zhou
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.